Time in Range Clinical Trial
Official title:
Feasibility of DPP-4 Inhibitor for the Treatment of Iftar-Related Glycemic Excursions in Patients With Type 1 Diabetes on MiniMedâ„¢ 780G Advanced Hybrid Closed Loop System
Background: Ramadan Iftar meal typically causes glucose excursions. Dipeptidyl peptidase-4 inhibitors increase serum concentrations of glucagon-like peptide-1 and thus, decrease blood glucose levels with low risk of hypoglycemia. Aim: To investigate the efficacy and safety of vildagliptin as an add-on therapy among adolescents and young adults with type 1 diabetes mellitus (T1DM) on glucose excursions of Iftar Ramadan meals and glycemic metrics during advanced hybrid closed-loop (AHCL) treatment.
Current management of people with type 1 diabetes mellitus (T1DM) on intensive insulin therapy recognizes carbohydrates as the most important determinant of postprandial glycaemia; hence, worldwide guidelines recommend carbohydrates counting for determining pre-prandial insulin doses. Currently, the insulin to carbohydrate ratio (ICR) is frequently used to calculate the meal insulin dose. However, ICRs are considered difficult, ineffective and inaccurate for some patient, with an estimation error of around 20% in adults demonstrating only modest improvements in glycated hemoglobin (HbA1c). This lack of effectiveness and the wide variability using ICRs suggests it should be improved upon. However, there have been only a few randomized control studies that investigated the efficacy and safety of DPP-4 inhibitors as an add-on drug in patients treated with basal insulin. Therefore, we conducted a one-month randomized control trial to investigate the efficacy and safety of DPP-4 inhibitors as an add-on therapy among adolescents and young adults with T1DM on glucose excursions of Iftar Ramadan meals and glucometrics during AHCL treatment . ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04682795 -
Comparison of Safety and Efficacy of Needle-Free Injector and Insulin Pen in Patients With T2DM
|
N/A | |
Recruiting |
NCT05389839 -
Insulin Dose Calculation Software in Insulin Therapy
|
N/A | |
Completed |
NCT04711382 -
The Use of Faster Acting Aspart in Type 1 Diabetes Patients
|
||
Recruiting |
NCT05947916 -
Real Time Continuous Glucose Monitoring System in T2DM With Pregnacy
|
N/A | |
Recruiting |
NCT04965051 -
Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T1DM
|
N/A |